SEC Form S-1/A filed by Yield10 Bioscience Inc. (Amendment)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
under the
SECURITIES ACT OF 1933
|
Delaware
(State or other jurisdiction of
incorporation or organization) |
| |
2870
(Primary Standard Industrial
Classification Code Number) |
| |
04-3158289
(IRS Employer
Identification No.) |
|
Woburn, Massachusetts 01801
(617) 583-1700
President & Chief Executive Officer
Yield10 Bioscience, Inc.
19 Presidential Way
Woburn, Massachusetts 01801
(617) 583-1700
Covington & Burling LLP
One International Place, Suite 1020
Boston, Massachusetts 02110
(617) 603-8805
From time to time after this registration statement becomes effective.
|
Large accelerated filer
☐
|
| |
Accelerated filer
☐
|
|
|
Non-accelerated filer
☒
|
| |
Smaller reporting company
☒
|
|
| | | |
Emerging growth company
☐
|
|
| | | | | 1 | | | |
| | | | | 5 | | | |
| | | | | 7 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 10 | | | |
| | | | | 13 | | | |
| | | | | 15 | | | |
| | | | | 16 | | | |
| | | | | 19 | | | |
| | | | | 19 | | | |
| | | | | 19 | | | |
| | | | | 19 | | | |
| | | | | 20 | | |
Warrants
| | |
Years Ended December 31,
|
| |||||||||
(in thousands, except share and per share amounts)
|
| |
2023
|
| |
2022
|
| ||||||
Net loss
|
| | | $ | (14,455) | | | | | $ | (13,566) | | |
Basic and diluted net loss per share
|
| | | $ | (1.82) | | | | | $ | (2.76) | | |
Number of shares used in per share calculations (basic and diluted)
|
| | | | 7,946,281 | | | | | | 4,914,565 | | |
Shares of common stock outstanding at year end
|
| | | | 12,032,425 | | | | | | 4,944,202 | | |
| | |
Shares
|
| |
Par Value
|
| ||||||
Balance, December 31, 2021 (in thousands, except share and per share amounts)
|
| | | | 4,881,851 | | | | | $ | 49 | | |
Issuance of common stock for 401(k) match
|
| | | | 36,706 | | | | |
|
—
|
| |
Issuance of common stock upon vesting of restricted stock units
|
| | | | 25,645 | | | | |
|
—
|
| |
Balance, December 31, 2022
|
| | | | 4,944,202 | | | | | $ | 49 | | |
Issuance of common stock for 401(k) match
|
| | | | 119,971 | | | | | | 1 | | |
Issuance of common stock under At-the-Market offering, net of issuance costs
|
| | | | 94,665 | | | | | | 1 | | |
Issuance of common stock upon vesting of restricted stock units
|
| | | | 17,640 | | | | | | — | | |
Issuance of common stock and warrants in equity offerings, net of issuance
costs |
| | | | 6,756,710 | | | | | | 68 | | |
Issuance of common stock for director compensation
|
| | | | 99,237 | | | | | | 1 | | |
Balance, December 31, 2023
|
| | | | 12,032,425 | | | | | | 120 | | |
| | |
Years Ended December 31,
|
| |||||||||
Unaudited (in thousands, except share and per share amounts)
|
| |
2023
|
| |
2022
|
| ||||||
Net loss
|
| | | $ | (14,455) | | | | | $ | (13,566) | | |
Basic and diluted net loss per share
|
| | | $ | (43.66) | | | | | $ | (66.25) | | |
Number of shares used in per share calculations (basic and diluted)
|
| | | | 331,101 | | | | | | 204,780 | | |
| | |
Years Ended December 31,
|
| |||||||||
Unaudited (in thousands, except share and per share amounts)
|
| |
2023
|
| |
2022
|
| ||||||
Shares of common stock outstanding at year end
|
| | | | 501,357 | | | | | | 206,015 | | |
| | |
Shares
|
| |
Par Value
|
| ||||||
Balance, December 31, 2021 (Unaudited, in thousands, except share and per share amounts)
|
| | | | 203,417 | | | | | $ | 2 | | |
Issuance of common stock for 401(k) match
|
| | | | 1,529 | | | | |
|
—
|
| |
Issuance of common stock upon vesting of restricted stock units
|
| | | | 1,069 | | | | |
|
—
|
| |
Balance, December 31, 2022
|
| | | | 206,015 | | | | | $ | 2 | | |
Issuance of common stock for 401(k) match
|
| | | | 4,998 | | | | | | — | | |
Issuance of common stock under At-the-Market offering, net of issuance costs
|
| | | | 3,945 | | | | | | — | | |
Issuance of common stock upon vesting of restricted stock units
|
| | | | 735 | | | | | | — | | |
Issuance of common stock and warrants in equity offerings, net of issuance costs
|
| | | | 281,530 | | | | | $ | 3 | | |
Issuance of common stock for director compensation
|
| | | | 4,131 | | | | | | — | | |
Balance, December 31, 2023
|
| | | | 501,357 | | | | | $ | 5 | | |
| | |
Prior to the Offering
|
| | | | | | | |
After the Offering
|
| ||||||||||||||||||
Selling Security Holder(1)
|
| |
Number of Shares
of Common Stock Beneficially Owned(2) |
| |
Percent of
Common Stock Outstanding(3) |
| |
Maximum Number
of Shares of Common Stock Being Registered for Resale |
| |
Number of
Shares of Common Stock Beneficially Owned(4) |
| |
Percent of
Common Stock Outstanding(3)(4) |
| |||||||||||||||
Armistice Capital Master Fund Ltd.(5)
|
| | | | 230,142 | | | | | | 28.9% | | | | | | 153,428 | | | | | | 76,714 | | | | | | 11.9% | | |
Brio Capital Master Fund Ltd.(6)
|
| | | | 45,410 | | | | | | 6.8% | | | | | | 29,167 | | | | | | 16,243 | | | | | | 2.5% | | |
L1 Capital Global Opportunities Master Fund(7)
|
| | | | 22,916 | | | | | | 3.5% | | | | | | 8,333 | | | | | | 14,583 | | | | | | 2.2% | | |
Lind Global
Fund II LP(8) |
| | | | 62,500 | | | | | | 9.1% | | | | | | 41,667 | | | | | | 20,833 | | | | | | 3.2% | | |
S.H.N. Financial Investments Ltd.(9)
|
| | | | 50,000 | | | | | | 7.4% | | | | | | 33,333 | | | | | | 16,667 | | | | | | 2.6% | | |
Total | | | | | | | | | | | | | | | | | 265,928 | | | | | | | | | | | | | | |
Yield10 Bioscience, Inc.
19 Presidential Way
Woburn, MA 01801
(617)583-1700
![[MISSING IMAGE: lg_yield10bioscience-4c.jpg]](https://www.sec.gov/Archives/edgar/data/0001121702/000110465924065622/lg_yield10bioscience-4c.jpg)
| | |
Amount to be paid
|
| |||
SEC registration fee
|
| | | $ | 244.93 | | |
Legal fees and expenses
|
| | | | 65,000.00 | | |
Accounting fees and expenses
|
| | | | 36,000.00 | | |
Total
|
| | | $ | 101,244.93 | | |
|
Exhibit
Number |
| |
Exhibit Description
|
| |
Filed
Herewith |
| |
Incorporated
by Reference herein from Form or Schedule |
| |
Filing Date
|
| |
SEC File/
Reg. Number |
|
| 3.1.1 | | | | | | | |
Form 10-Q
(Exhibit 3.1) |
| | 8/9/2018 | | | 001-33133 | | |
| 3.1.2 | | | | | | | |
Form 8-K
(Exhibit 3.1) |
| | 1/15/2020 | | | 001-33133 | | |
| 3.1.3 | | | | | | | |
Form 8-K
(Exhibit 3.1) |
| | 11/20/2019 | | | 001-33133 | | |
| 3.1.4 | | | | | | | |
Form 8-K
(Exhibit 3.2) |
| | 11/20/2019 | | | 001-33133 | | |
| 3.2 | | | | | | | |
Form 10-Q
(Exhibit 3.1) |
| | 11/10/2021 | | | 001-33133 | | |
| 4.1 | | | | | | | |
Form 10-Q
(Exhibit 4.1) |
| | 11/12/2020 | | | 001-33133 | | |
| 4.2 | | | | | | | |
Form 8-K
(Exhibit 4.1) |
| | 11/20/2019 | | | 001-33133 | | |
| 4.3 | | | | | | | |
Form 8-K
(Exhibit 4.1) |
| | 5/1/2023 | | | 001-33133 | | |
| 4.4 | | | | | | | |
Form 8-K
(Exhibit 4.1) |
| | 5/4/2023 | | | 001-33133 | | |
| 4.5 | | | | | | | |
Form 8-K
(Exhibit 4.2) |
| | 5/4/2023 | | | 001-33133 | | |
| 4.6 | | | | | | | |
Form S-1/A
(Exhibit 4.9) |
| | 8/2/2023 | | | 333-273240 | | |
| 4.7 | | | | | | | |
Form 8-K
(Exhibit 4.1) |
| | 3/22/2024 | | | 001-33133 | | |
| 5.1 | | | | | | | | | | | | | | | | |
| 10.1† | | | | | | | |
Form S-1/A
(Exhibit 10.3) |
| | 10/20/2006 | | | 333-135760 | | |
| 10.1.1† | | | | | | | |
Form S-1/A
(Exhibit 10.3.1) |
| | 10/20/2006 | | | 333-135760 | | |
| 10.1.2† | | | | | | | |
Form S-1/A
(Exhibit 10.3.2) |
| | 10/20/2006 | | | 333-135760 | | |
| 10.1.3† | | | | | | | |
Form S-1/A
(Exhibit 10.3.3) |
| | 10/20/2006 | | | 333-135760 | | |
| 10.2† | | | | | | | |
Form 10-Q
(Exhibit 10.1) |
| | 8/13/2015 | | | 001-33133 | |
|
Exhibit
Number |
| |
Exhibit Description
|
| |
Filed
Herewith |
| |
Incorporated
by Reference herein from Form or Schedule |
| |
Filing Date
|
| |
SEC File/
Reg. Number |
|
| 10.2.1† | | | | | | | |
Form 10-K
(Exhibit 10.3.1) |
| | 3/25/2015 | | | 001-33133 | | |
| 10.2.2† | | | | | | | |
Form 10-K
(Exhibit 10.3.2) |
| | 3/25/2015 | | | 001-33133 | | |
| 10.2.3† | | | | | | | |
Form 10-K
(Exhibit 10.3.3) |
| | 3/25/2015 | | | 001-33133 | | |
| 10.3† | | | | | | | |
Form 8-K
(Exhibit 10.1) |
| | 5/30/2023 | | | 001-33133 | | |
| 10.3.1† | | | | | | | |
Form 10-K
(Exhibit 10.2.5) |
| | 3/28/2019 | | | 001-33133 | | |
| 10.3.2† | | | | | | | |
Form 10-K
(Exhibit 10.2.6) |
| | 3/25/2020 | | | 001-33133 | | |
| 10.4† | | | | | | | |
Form 10-K
(Exhibit 10.3) |
| | 3/30/2017 | | | 001-33133 | | |
| 10.5† | | | | | | | |
Form 10-K
(Exhibit 10.5) |
| | 4/1/2024 | | | 001-33133 | | |
| 10.6† | | | | | | | |
Form 10-K
(Exhibit 10.4) |
| | 3/30/2017 | | | 001-33133 | | |
| 10.7† | | | | | | | |
Form 10-K
(Exhibit 10.7) |
| | 4/1/2024 | | | 001-33133 | | |
| 10.8† | | | | | | | |
Form 10-K
(Exhibit 10.6) |
| | 3/30/2017 | | | 001-33133 | | |
| 10.9† | | | | | | | |
Form 10-K
(Exhibit 10.9) |
| | 4/1/2024 | | | 001-33133 | | |
| 10.10† | | | | | | | |
Form 10-K
(Exhibit 10.8) |
| | 3/30/2017 | | | 001-33133 | | |
| 10.11† | | | | | | | |
Form 10-K
(Exhibit 10.11) |
| | 4/1/2024 | | | 001-33133 | | |
| 10.12† | | | | | | | |
Form 10-K
(Exhibit 10.9) |
| | 3/30/2017 | | |
001-33133
|
|
|
Exhibit
Number |
| |
Exhibit Description
|
| |
Filed
Herewith |
| |
Incorporated
by Reference herein from Form or Schedule |
| |
Filing Date
|
| |
SEC File/
Reg. Number |
|
| 10.13† | | | | | | | |
Form S/1/A
(Exhibit 10.14) |
| |
10/20/2006
|
| |
333-135760
|
| |
| 10.14 | | | | | | | |
Form 8-K
(Exhibit 10.1) |
| | 6/17/2015 | | | 001-33133 | | |
| 10.15 | | | | | | | |
Form 8-K
(Exhibit 10.1) |
| | 1/26/2016 | | | 001-33133 | | |
| 10.16 | | | | | | | |
Form 10-K
(Exhibit 10.20) |
| | 3/30/2017 | | | 001-33133 | | |
| 10.17 | | | | | | | |
Form 8-K
(Exhibit 10.1) |
| | 7/5/2017 | | | 001-33133 | | |
| 10.18@ | | | | | | | |
Form 10-Q
(Exhibit 10.2) |
| | 8/9/2018 | | | 001-33133 | | |
| 10.19 | | | | | | | |
Form 8-K
(Exhibit 10.1) |
| | 3/15/2019 | | | 001-33133 | | |
| 10.20 | | | | | | | |
Form 8-K
(Exhibit 10.1) |
| |
11/20/2019
|
| | 001-33133 | | |
| 10.21 | | | | | | | |
Form 8-K
(Exhibit 10.1) |
| | 8/25/2020 | | | 001-33133 | | |
| 10.22 | | | | | | | |
Form 10-K
(Exhibit 10.18) |
| | 3/14/2023 | | | 001-33133 | | |
| 10.23 | | | | | | | |
Form 8-K
(Exhibit 1.1) |
| | 1/24/2023 | | | 001-33133 | | |
| 10.24 | | | | | | | |
Form 8-K
(Exhibit 10.1) |
| | 5/1/2023 | | |
001-33133
|
|
|
Exhibit
Number |
| |
Exhibit Description
|
| |
Filed
Herewith |
| |
Incorporated
by Reference herein from Form or Schedule |
| |
Filing Date
|
| |
SEC File/
Reg. Number |
|
| 10.25 | | | | | | | |
Form 8-K
(Exhibit 10.1) |
| | 5/4/2023 | | | 001-33133 | | |
| 10.26 | | | | | | | |
Form S-1/A
(Exhibit 10.21) |
| | 8/2/2023 | | |
333-273240
|
| |
| 10.27 | | | | | | | |
Form 8-K
(Exhibit 10.1) |
| | 3/22/2024 | | | 001-33133 | | |
| 16.1 | | | | | | | |
Form 8-K
(Exhibit 16.1) |
| | 2/6/2024 | | | 001-33133 | | |
| 21.1 | | | | | | | |
Form 10-K
(Exhibit 21.1) |
| | 3/16/2021 | | | 001-33133 | | |
| 23.1 | | | Consent of RSM US LLP, an independent registered public accounting firm. | | | X | | | | | | | | | | |
| 23.2 | | | | | X | | | | | | | | | | | |
| 23.3 | | | | | | | | | | | | | | | | |
| 24.1 | | | Power of Attorney (included in the signature pages to the Registration Statement). | | | | | | | | | | | | | |
| 101.INS | | | XBRL Instance Document. | | | X | | | | | | | | | | |
| 101.SCH | | | XBRL Taxonomy Extension Schema. | | | X | | | | | | | | | | |
|
101.CAL
|
| | XBRL Taxonomy Extension Calculation Linkbase. | | | X | | | | | | | | | | |
|
101.DEF
|
| | XBRL Taxonomy Extension Definition Linkbase. | | | X | | | | | | | | | | |
| 101.LAB | | | XBRL Taxonomy Extension Label Linkbase. | | | X | | | | | | | | | | |
| 101.PRE | | | XBRL Taxonomy Extension Presentation Linkbase. | | | X | | | | | | | | | | |
| 107 | | | | | | | | | | | | | | | |
| | | | YIELD10 BIOSCIENCE, INC. | | |||
| | | | By | | |
/s/ Oliver P. Peoples
Oliver P. Peoples
President and Chief Executive Officer |
|
|
Name
|
| |
Title
|
| |
Date
|
|
|
/s/ OLIVER P. PEOPLES
Oliver P. Peoples, Ph.D.
|
| | President and Chief Executive Officer and Director (Principal Executive Officer) | | |
May 28, 2024
|
|
|
/s/ CHARLES B. HAASER
Charles B. Haaser
|
| | Vice President, Finance, and Chief Accounting Officer (Principal Financial and Accounting Officer) | | |
May 28, 2024
|
|
|
*
Sherri M. Brown, Ph.D.
|
| | Director | | |
May 28, 2024
|
|
|
*
Richard W. Hamilton, Ph.D.
|
| | Director | | |
May 28, 2024
|
|
|
*
Willie Loh, Ph.D.
|
| | Director | | |
May 28, 2024
|
|
|
*
Anthony J. Sinskey, Sc.D.
|
| | Director | | |
May 28, 2024
|
|
|
*
Robert L. Van Nostrand
|
| | Chairman | | |
May 28, 2024
|
|